Jeremie Vendome
Overview
Explore the profile of Jeremie Vendome including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michino M, Khan T, Miller M, Fukase Y, Vendome J, Adura C, et al.
ACS Med Chem Lett
. 2024 Apr;
15(4):524-532.
PMID: 38628784
Eleven-nineteen leukemia (ENL) is an epigenetic reader protein that drives oncogenic transcriptional programs in acute myeloid leukemia (AML). AML is one of the deadliest hematopoietic malignancies, with an overall 5-year...
2.
Michino M, Beautrait A, Boyles N, Nadupalli A, Dementiev A, Sun S, et al.
ACS Bio Med Chem Au
. 2023 Dec;
3(6):507-515.
PMID: 38144256
Lpd (lipoamide dehydrogenase) in (Mtb) is required for virulence and is a genetically validated tuberculosis (TB) target. Numerous screens have been performed over the last decade, yet only two inhibitor...
3.
Chen W, Cui D, Jerome S, Michino M, Lenselink E, Huggins D, et al.
J Chem Inf Model
. 2023 May;
63(10):3171-3185.
PMID: 37167486
In the hit identification stage of drug discovery, a diverse chemical space needs to be explored to identify initial hits. Contrary to empirical scoring functions, absolute protein-ligand binding free-energy perturbation...
4.
Zhang H, Ginn J, Zhan W, Leung A, Liu Y, Toita A, et al.
J Med Chem
. 2023 Jan;
66(2):1484-1508.
PMID: 36630286
With increasing reports of resistance to artemisinins and artemisinin-combination therapies, targeting the proteasome is a promising strategy for antimalarial development. We recently reported a highly selective proteasome inhibitor with anti-malarial...
5.
Xu T, Zhu K, Beautrait A, Vendome J, Borrelli K, Abel R, et al.
J Chem Theory Comput
. 2022 Aug;
18(9):5710-5724.
PMID: 35972903
Homology models have been used for virtual screening and to understand the binding mode of a known active compound; however, rarely have the models been shown to be of sufficient...
6.
Zhang H, Ginn J, Zhan W, Liu Y, Leung A, Toita A, et al.
J Med Chem
. 2022 Jun;
65(13):9350-9375.
PMID: 35727231
With over 200 million cases and close to half a million deaths each year, malaria is a threat to global health, particularly in developing countries. , the parasite that causes...
7.
Small-Saunders J, Hagenah L, Wicht K, Dhingra S, Deni I, Kim J, et al.
PLoS Pathog
. 2022 Feb;
18(2):e1010278.
PMID: 35130315
Multidrug-resistant Plasmodium falciparum parasites have emerged in Cambodia and neighboring countries in Southeast Asia, compromising the efficacy of first-line antimalarial combinations. Dihydroartemisinin + piperaquine (PPQ) treatment failure rates have risen...
8.
Ottavi S, Scarry S, Mosior J, Ling Y, Roberts J, Singh A, et al.
J Med Chem
. 2022 Jan;
65(3):1996-2022.
PMID: 35044775
A newly validated target for tuberculosis treatment is phosphopantetheinyl transferase, an essential enzyme that plays a critical role in the biosynthesis of cellular lipids and virulence factors in . The...
9.
Loukeris M, Sanghai Z, Vendome J, Hendrickson W, Kloss B, Mancia F
J Mol Biol
. 2021 May;
433(15):167055.
PMID: 34022208
We describe an enhancement of traditional genomics-based approaches to improve the success of structure determination of membrane proteins. Following a broad screen of sequence space to identify initial expression-positive targets,...
10.
Zhang H, Hsu H, Kahne S, Hara R, Zhan W, Jiang X, et al.
J Med Chem
. 2021 May;
64(9):6262-6272.
PMID: 33949190
Treatment of tuberculosis (TB) currently takes at least 6 months. Latent (Mtb) is phenotypically tolerant to most anti-TB drugs. A key hypothesis is that drugs that kill nonreplicating (NR) Mtb...